Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arbutus Biopharma Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABUS
Nasdaq
8731
https://www.arbutusbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arbutus Biopharma Corp
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Nov 9th, 2023 9:24 pm
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver MeetingĀ®
- Nov 9th, 2023 9:01 pm
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 2:12 pm
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
- Nov 9th, 2023 10:10 am
Arbutus to Present at Jefferies London Healthcare Conference
- Nov 8th, 2023 12:30 pm
Q3 2023 Arbutus Biopharma Corp Earnings Call
- Nov 8th, 2023 6:16 am
Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results
- Nov 7th, 2023 1:05 pm
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 7th, 2023 12:30 pm
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
- Nov 7th, 2023 12:15 pm
12 Best Micro Cap Stocks To Invest In
- Oct 30th, 2023 1:32 pm
Will Arbutus Biopharma (NASDAQ:ABUS) Spend Its Cash Wisely?
- Oct 24th, 2023 2:28 pm
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
- Oct 24th, 2023 11:30 am
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
- Oct 18th, 2023 11:30 am
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver MeetingĀ® 2023
- Oct 11th, 2023 12:05 pm
Arbutus BioPharma narrows research focus to extend cash runway
- Sep 12th, 2023 2:56 pm
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
- Sep 12th, 2023 12:58 pm
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
- Sep 11th, 2023 8:15 pm
Arbutus to Participate in Two Upcoming Investor Conferences
- Sep 7th, 2023 11:30 am
Arbutus Biopharma (NASDAQ:ABUS) shareholders have endured a 78% loss from investing in the stock five years ago
- Aug 26th, 2023 2:41 pm
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
- Aug 4th, 2023 7:29 pm
Scroll